NEWTON CHARLES W. (Chief Financial Officer) purchased 200K shares of LYELL IMMUNOPHARMA, INC. on the open market
Open‑market purchase worth $111.6K. The strongest form of insider conviction signal.
P · 1 purchase
Filed: 3/18/2025ACC: 0001415889-25-008517
Officer· Chief Financial Officer
Since Jun 2021
+200K
Net shares
Net buyer
$111.6K
Total acquired
1
Open market trades
1B · 0S
1
Total transactions
200K acquired
Non-Derivative Transactions1
Common Stock
Indirect
Shares
+200K
Price / share
$0.56
Trade value
$111.62K
% of position
New position
3/17/2025
0.00→200K
Total
Net shares
+200K
Net value
$111.62K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Indirect | 3/17/2025 | P · Purchase | +200K | $0.56 | $111.62K | New position | 0.00 | 200K |
| Total | +200K | $111.62K | ||||||
Derivative Transactions0
No derivative transactions reported
Non-Derivative Holdings (Post-Transaction)1
Common Stock
DirectShares owned172.72K
Total
172.72K direct172.72K
| Security Title | Shares Owned | Ownership Type |
|---|---|---|
| Common Stock | 172.72K | Direct |
| Total | 172.72K | 172.72K direct |
Derivative Holdings (Post-Transaction)0
No derivative holdings reported